Study to Assess the Relative Potency of Multiple Oral Doses of LUM001 and SHP626 in Overweight and Obese Adults as Assessed by Fecal Bile Acid Excretion
Completed
Mirum Pharmaceuticals, Inc.
Phase 1
The purpose of this study is to assess the relative potency of multiple oral doses of LUM001
and SHP626 administered for 7 days as assessed by fecal bile acid excretion in overweight and
obese adult subjects. This study is designed to address the relative potency question for the
first time in the same.
Study to Assess the Relative Potency of Multiple Oral Doses of LUM001 and SHP626 in Overweight and Obese Adults as Assessed by Fecal Bile Acid Excretion
Completed
Shire
Phase 1
The purpose of this study is to assess the relative potency of multiple oral doses of LUM001
and SHP626 administered for 7 days as assessed by fecal bile acid excretion in overweight and
obese adult subjects. This study is designed to address the relative potency question for the
first time in the same.
Volixibat (SHP626) in the Treatment of Adults With Nonalcoholic Steatohepatitis (NASH)
Terminated
Mirum Pharmaceuticals, Inc.
Phase 2
The purpose of this study is to determine if the investigational treatment volixibat (SHP626)
is safe, tolerable and effective in adults with nonalcoholic steatohepatitis (NASH).
Volixibat (SHP626) in the Treatment of Adults With Nonalcoholic Steatohepatitis (NASH)
Terminated
Shire
Phase 2
The purpose of this study is to determine if the investigational treatment volixibat (SHP626)
is safe, tolerable and effective in adults with nonalcoholic steatohepatitis (NASH).
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)
Recruiting
Mirum Pharmaceuticals, Inc.
Phase 2
The purpose of this clinical research study is to learn more about the use of the study
medicine, volixibat, for the treatment of pruritus (itching) associated with Primary
Sclerosing Cholangitis (PSC), and to assess the possible impact on the disease progression of
PSC.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
